Cargando…

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

Immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, are used in the routine treatment for multiple myeloma (MM) patients. Cereblon (CRBN) is the direct molecular target of IMiDs. While CRBN is not an essential gene for MM cell proliferation, the frequency of CRBN genetic aberrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karagoz, Kubra, Stokes, Matthew, Ortiz-Estévez, María, Towfic, Fadi, Flynt, Erin, Gooding, Sarah, Pierceall, William, Thakurta, Anjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864318/ https://www.ncbi.nlm.nih.gov/pubmed/35222546 http://dx.doi.org/10.3389/fgene.2022.831779

Ejemplares similares

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways
por: Ortiz-Estévez, María, et al.
Publicado: (2021)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples
por: Ren, Yan, et al.
Publicado: (2016)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
por: Bauer, Michael A., et al.
Publicado: (2020)

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
por: Hagner, Patrick R., et al.
Publicado: (2022)

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma
por: Chang, Xiubao, et al.
Publicado: (2017)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
por: Wester, R., et al.
Publicado: (2023)

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
por: Sudha, Parvathi, et al.
Publicado: (2022)

Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
por: Costacurta, Matteo, et al.
Publicado: (2021)

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
por: Butrym, Aleksandra, et al.
Publicado: (2017)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
por: Mou, Haiwei, et al.
Publicado: (2017)

Chemical Ligand Space of Cereblon
por: Boichenko, Iuliia, et al.
Publicado: (2018)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
por: Tachita, Takuto, et al.
Publicado: (2020)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
por: Charliński, Grzegorz, et al.
Publicado: (2021)

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

SpliceAI-10k calculator for the prediction of pseudoexonization, intron retention, and exon deletion
por: Canson, Daffodil M, et al.
Publicado: (2023)

Detection of internal exon deletion with exon Del
por: Guo, Yan, et al.
Publicado: (2014)

Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
por: Xu, Qinqin, et al.
Publicado: (2016)

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

The effect of a single SMARCA4 exon deletion on RNA splicing: Implications for variant classification
por: Byrjalsen, Anna, et al.
Publicado: (2023)

Effect of exonic splicing regulation on synonymous codon usage in alternatively spliced exons of Dscam
por: Takahashi, Aya
Publicado: (2009)

The Usage of Exon-Exon Splice Junctions for the Detection of Alternative Splicing using the REIDS model
por: Van Moerbeke, Marijke, et al.
Publicado: (2018)

Structural Dynamics of the Cereblon Ligand Binding Domain
por: Hartmann, Marcus D., et al.
Publicado: (2015)

Structural basis of thalidomide enantiomer binding to cereblon
por: Mori, Tomoyuki, et al.
Publicado: (2018)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
por: Gasic, Ivana, et al.
Publicado: (2020)

UDP-glucose, cereblon-dependent proinsulin degrader
por: Cho, Jaeyong, et al.
Publicado: (2022)

MBNL1 and PTB cooperate to repress splicing of Tpm1 exon 3
por: Gooding, Clare, et al.
Publicado: (2013)

Predicting mutually exclusive spliced exons based on exon length, splice site and reading frame conservation, and exon sequence homology
por: Pillmann, Holger, et al.
Publicado: (2011)

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2014)

Mitochondrial cereblon functions as a Lon-type protease
por: Kataoka, Kosuke, et al.
Publicado: (2016)

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0v7tfp5p2pjn6kh92me54f78hn